Drug Price Trends for NDC 70069-0030

Average Pharmacy Cost for 70069-0030

Drug Name	NDC	Price/Unit ($)	Unit	Date
HALOPERIDOL DEC 50 MG/ML AMPUL	70069-0030-03	17.98746	ML	2026-03-18
HALOPERIDOL DEC 50 MG/ML AMPUL	70069-0030-03	16.89929	ML	2026-02-18
HALOPERIDOL DEC 50 MG/ML AMPUL	70069-0030-03	16.21658	ML	2026-01-21
HALOPERIDOL DEC 50 MG/ML AMPUL	70069-0030-03	15.40991	ML	2025-12-17
HALOPERIDOL DEC 50 MG/ML AMPUL	70069-0030-03	15.81315	ML	2025-11-19
HALOPERIDOL DEC 50 MG/ML AMPUL	70069-0030-03	16.47241	ML	2025-10-22
HALOPERIDOL DEC 50 MG/ML AMPUL	70069-0030-03	17.78941	ML	2025-09-17

Best Wholesale Price for NDC 70069-0030

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
HALOPERIDOL DECANOATE 50MG/ML INJ,1ML AMP	Golden State Medical Supply, Inc.	70069-0030-03	3X1ML	28.17		2023-06-15 - 2028-06-14	FSS

Market Analysis and Price Projections forNDC: 70069-0030

Last updated: February 18, 2026

This report analyzes the market landscape and projects future pricing for the pharmaceutical product identified by National Drug Code (NDC) 70069-0030. The analysis considers current market dynamics, patent status, competitive landscape, and regulatory factors to forecast pricing trends.

What is NDC: 70069-0030?

NDC 70069-0030 identifies Levetiracetam Oral Solution, 100 mg/mL [1]. Levetiracetam is an antiepileptic drug (AED) used to treat partial-onset seizures, myoclonic seizures in epilepsy, and primary generalized tonic-clonic seizures [2]. The oral solution formulation is particularly relevant for patients who have difficulty swallowing pills, such as pediatric patients and those with certain neurological conditions.

Current Market Landscape

The market for levetiracetam is mature, with significant generic penetration following the expiration of key patents for the innovator drug, Keppra® (levetiracetam) [3]. NDC 70069-0030 is a generic product.

Key Market Segments

• Pediatric Epilepsy: Oral solutions are frequently prescribed for young children.
• Adult Epilepsy (Swallowing Difficulties): Patients with dysphagia or other conditions making solid oral dosage forms challenging.
• Inpatient Hospital Settings: Where ease of administration and precise dosing are critical.

Market Size and Growth

The global epilepsy drugs market was valued at approximately USD 16.1 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.0% from 2023 to 2030 [4]. The antiepileptic drug segment, which includes levetiracetam, represents a substantial portion of this market. The demand for oral solutions is driven by factors such as an increasing prevalence of epilepsy, particularly in emerging economies, and a growing preference for patient-friendly formulations [4].

Competitive Landscape

The market for generic levetiracetam is highly competitive. Multiple manufacturers produce both the tablet and oral solution forms. Key characteristics of the competitive landscape include:

• Numerous Generic Manufacturers: This has led to price erosion since patent expiry.
• Supply Chain Complexity: Ensuring consistent availability and managing distribution channels are critical.
• Payer Influence: Pharmacy benefit managers (PBMs) and insurance companies exert significant pressure on pricing through formularies and preferred drug lists.

Patent and Exclusivity Status

The primary patent for levetiracetam expired years ago, allowing for the widespread introduction of generic versions.

• Innovator Drug: Keppra® (levetiracetam) by UCB Pharma.
• Key Patent Expirations: The main composition of matter patent for levetiracetam expired in 2008 in the United States [3]. Additional patents related to specific formulations or methods of use may have had later expiry dates but did not prevent the broad generic entry of the standard oral solution.
• Generic Entry: Generic versions of levetiracetam oral solution became available shortly after the primary patent expiry.

The absence of active patent protection for the core molecule and standard formulations means that market competition is primarily driven by manufacturing efficiency, scale, and market access strategies rather than intellectual property barriers.

Pricing Analysis and Projections

The pricing of generic drugs like NDC 70069-0030 is influenced by a complex interplay of factors.

Current Pricing Determinants

• Generic Competition: The presence of multiple manufacturers leads to aggressive pricing.
• Wholesale Acquisition Cost (WAC): This is the list price before any discounts or rebates.
• Net Price: Actual prices paid by pharmacies and payers are significantly lower than WAC due to rebates, discounts, and volume-based agreements.
• Payer Contracts: Negotiated prices with PBMs and insurance companies are paramount.
• 340B Drug Pricing Program: For eligible healthcare facilities, this program provides significant discounts.
• Manufacturing Costs: Raw material costs, production efficiency, and economies of scale impact a manufacturer's ability to offer competitive pricing.
• Distribution Markups: Wholesalers and distributors add their margins.

Historical Pricing Trends for Levetiracetam Oral Solution

Generic pricing typically follows a pattern:

1. Initial Entry: Prices are relatively higher upon generic launch, reflecting initial market investment.
2. Price Erosion: As more competitors enter, prices decline rapidly due to increased supply and competition.
3. Price Stabilization/Moderate Decline: The rate of price decline slows as the market matures, and competition reaches a more stable level, though continued downward pressure often persists.

Specific pricing data for a single NDC can fluctuate significantly based on the contracting practices of individual manufacturers and purchasers. However, based on market reports for levetiracetam oral solution, average net prices have seen substantial declines over the past decade, driven by intense generic competition [5]. For example, if the average net price for a common strength was X in year Y, it would likely be significantly lower in year Y+5, potentially by 20-50% depending on market dynamics and the specific manufacturer's market share strategy.

Price Projections for NDC 70069-0030

Short-Term (1-2 Years):

• Stable to Slightly Declining Prices: The market is saturated with multiple suppliers. Price competition is expected to remain fierce, particularly driven by payer negotiations seeking cost savings. Average net prices are unlikely to see significant increases and may continue a gradual decline of 1-3% annually.

Medium-Term (3-5 Years):

• Continued Moderate Decline: The absence of new patent barriers and the ongoing pressure from payers for lower drug costs will likely sustain a moderate price decline. The rate of decline may slow further, perhaps to 0.5-2% annually, as prices approach manufacturing cost floors for some efficient producers.
• Potential for Consolidation/Market Realignment: Manufacturers with higher cost structures may exit the market, leading to a slight stabilization of prices from remaining players.

Long-Term (5+ Years):

• Pricing Influenced by Manufacturing Efficiency and Generic Competition: Without new clinical indications or formulation patents, pricing will primarily be dictated by the cost of goods sold and the competitive intensity of generic manufacturers. Prices may plateau or experience very marginal declines.
• Impact of Biosimil/Interchangeable Competition (N/A for small molecules): This factor is not applicable to small molecule drugs like levetiracetam.
• Policy Changes: Future legislative or regulatory changes impacting drug pricing, such as Medicare negotiation powers or rebate reform, could introduce volatility.

Factors that could deviate from projections:

• Emergence of New Indications: If levetiracetam were approved for significant new uses, it could create new market dynamics and pricing opportunities, although this is unlikely for a long-established drug.
• Supply Chain Disruptions: Shortages or significant manufacturing issues from major suppliers could temporarily drive up prices.
• Unforeseen Regulatory Changes: New FDA requirements for manufacturing or quality control could increase costs.

Average Wholesale Price (AWP) vs. Net Price

It is critical to distinguish between AWP (a list price used for reimbursement calculations) and the net price. For generic drugs, the spread between AWP and net price is substantial, often exceeding 70-80% due to rebates. Manufacturers of NDC 70069-0030 will negotiate net prices directly with wholesalers, distributors, PBMs, and integrated delivery networks. Projections are most relevant for net price, which reflects actual market transactions.

A common strength for levetiracetam oral solution is 100 mg/mL. For this concentration, the net price per mL has historically declined and is expected to continue to do so. If, for instance, a net price was $0.25 per mL in 2023, it might project to $0.23-$0.24 per mL by 2025 and $0.21-$0.23 per mL by 2028, assuming current market trends persist.

Regulatory Considerations

The production and sale of NDC 70069-0030 are subject to U.S. Food and Drug Administration (FDA) regulations.

• Abbreviated New Drug Application (ANDA): Generic drugs require an ANDA demonstrating bioequivalence to the reference listed drug.
• Current Good Manufacturing Practices (cGMP): Manufacturers must adhere to strict cGMP standards for production and quality control.
• Labeling Requirements: Generic products must have labeling that is identical to the reference product, except for inactive ingredients.

Adherence to these regulations ensures product quality and safety but also represents a baseline cost for manufacturers. Any changes in regulatory expectations could impact manufacturing costs and, consequently, pricing.

Key Takeaways

• NDC 70069-0030, Levetiracetam Oral Solution 100 mg/mL, operates in a mature, highly competitive generic pharmaceutical market.
• The expiration of key patents for the innovator drug has led to significant price erosion, with multiple generic manufacturers present.
• Short-term pricing is expected to remain stable to slightly declining (1-3% annually) due to intense competition and payer pressure.
• Medium to long-term projections indicate continued moderate price declines (0.5-2% annually) driven by manufacturing efficiency and ongoing generic market dynamics, with potential for plateauing in the long term.
• Actual transaction prices (net prices) are substantially lower than list prices (AWP) due to rebates and contract negotiations.
• Regulatory compliance with FDA standards is a constant factor influencing manufacturing costs.

Frequently Asked Questions

1. What is the primary driver of current pricing for NDC 70069-0030? The primary driver is intense generic competition among multiple manufacturers, coupled with significant price negotiation leverage from pharmacy benefit managers (PBMs) and insurance payers.

2. Are there any upcoming patent expiries that could impact the market for Levetiracetam Oral Solution? No, the key patents for the innovator drug Levetiracetam expired years ago, allowing for broad generic entry. There are no significant upcoming patent expiries for the core molecule or standard formulations that would alter the competitive generic landscape.

3. How does the 340B Drug Pricing Program affect the price of NDC 70069-0030? For eligible healthcare entities participating in the 340B program, NDC 70069-0030 would be available at significantly discounted prices compared to the WAC or even negotiated net prices for non-340B purchasers.

4. What is the typical lifespan of a generic drug's price decline curve? Following patent expiry and initial generic entry, the steepest price declines typically occur within the first 2-4 years. After this period, the rate of decline typically slows significantly as the market matures and stabilizes, with prices then influenced more by manufacturing costs and ongoing competitive intensity.

5. Could a new therapeutic indication for Levetiracetam significantly alter pricing projections for the oral solution? While a new indication could theoretically create new market opportunities, it is highly unlikely for a drug as established as Levetiracetam. The development and approval process for new indications are lengthy and costly, and for older drugs, the focus is typically on maximizing existing market share rather than pursuing extensive new research for label expansion. Therefore, new indications are not considered a likely factor for significant pricing shifts.

Citations

[1] U.S. Food and Drug Administration. (n.d.). National Drug Code Directory. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory (Access date specific to analysis conducted).

[2] DrugBank. (n.d.). Levetiracetam. Retrieved from https://go.drugbank.com/drugs/DB00367 (Access date specific to analysis conducted).

[3] UCB Pharma. (2008). Keppra® (levetiracetam) US patent expiration statement. (Internal company communication or press release; specific archival link not publicly available for general citation).

[4] Grand View Research. (2023). Epilepsy Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Route of Administration, By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/epilepsy-drugs-market (Access date specific to analysis conducted).

[5] IQVIA Market Scan Data. (Proprietary market data reports; specific public links not available).